日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

XPO1抑制剂联合伊立替康在临床前结直肠癌模型中的疗效

Lentz, Robert W; Dominguez, Adrian T A; Balmaceda, Nicole Baranda; Arcaroli, John J; Bagby, Stacey M; Binns, Cameron A; Smoots, Stephen G; Jackson, Marilyn M; Macbeth, Morgan; Holmstoen, Tessa; Banerjee, Tapahsama; Whitty, Phaedra A; Yi, S Stephen; Lieu, Christopher H; Messersmith, Wells A; Pitts, Todd M

Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

新型CD47阻断联合疗法治疗难治性微卫星稳定型转移性结直肠癌的II期临床试验和临床前评估

Lentz, Robert W; Lang, Julie; Pitts, Todd M; Blatchford, Patrick; Hu, Junxiao; Jordan, Kimberly R; Van Bokhoven, Adrie; Bagby, Stacey M; Dominguez, Adrian T A; Binns, Cameron A; Robinson, Hannah R; Balmaceda, Nicole; Baiyee, Emily; Leal, Alexis D; Kim, Sunnie S; Davis, S Lindsey; Lieu, Christopher H; Wadlow, Raymond C; Spencer, Kristen; Scott, Aaron J; Boland, Patrick M; Hochster, Howard S; Messersmith, Wells A

Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer.

通过抑制 BCL-2 增强阿霉素在 p53 野生型和突变型三阴性乳腺癌中的活性

Schreiber Anna R, Smoots Stephen G, Jackson Marilyn M, Bagby Stacey M, Dus Evan D, Dominguez Adrian T A, Binns Cameron A, Pitts Todd M, Diamond Jennifer R